Concepedia

Author

Michael Lahn

Eli Lilly (United States)ORCID

Also Known As

Lahn,Michael, M Lahn, M. LAHN, M. Lahn, M. M. F. Lahn, M. M. Lahn, M.M. Lahn, MICHAEL LAHN, Michael Lahn, Michael M Lahn

220

Publications

4.7K

Citations

39

H-Index

110

Concepts

All Affiliations

Eli Lilly (United States)National Jewish HealthUniversity of Colorado DenverEli Lilly (United Kingdom)University Hospital Heidelberg
ML

About

Michael Lahn is an author at Eli Lilly (United States) specializing in medicine, immunology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

26

34

2.1K

2

Allergy

7

7

630

3

Health Sciences

5

5

209

4

Engineering

1

1

18

5

Allergy Medicine

1

1

123

Michael Lahn

×

64

Publications

4K

Citations

36

H-Index

YearCitations

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Alba A. Brandes, Santosh Kesari, Juan Manuel Sepúlveda-Sánchez,

Neuro-Oncology

2016

264

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

Davide Melisi, Rocio García‐Carbonero, Teresa Macarulla,

British Journal of Cancer

2018

262

Immunoregulatory Functions of γδ T Cells

Willi K. Born, Carol Cady, Jessica Jones‐Carson,

Advances in immunology

1998

197

Negative regulation of airway responsiveness that is dependent on γδ T cells and independent of αβ T cells

Michael Lahn, Arihiko Kanehiro, Katsuyuki Takeda,

Nature Medicine

1999

175

Phase III Study of Gemcitabine and Cisplatin With or Without Aprinocarsen, a Protein Kinase C-Alpha Antisense Oligonucleotide, in Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Jean‐Yves Douillard, P. Koralewski,

Journal of Clinical Oncology

2006

155

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Sandrine Faivre, Armando Santoro, Robin Kate Kelley,

Liver International

2019

134

Reduced SMAD7 Leads to Overactivation of TGF-β Signaling in MDS that Can Be Reversed by a Specific Inhibitor of TGF-β Receptor I Kinase

Li Zhou, Christine M. McMahon, Tushar D. Bhagat,

Cancer Research

2010

132

Different Potentials of γδ T Cell Subsets in Regulating Airway Responsiveness: Vγ1+ Cells, but Not Vγ4+ Cells, Promote Airway Hyperreactivity, Th2 Cytokines, and Airway Inflammation

Youn‐Soo Hahn, Christian Taube, Niyun Jin,

The Journal of Immunology

2004

130

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Antje Wick, Annick Desjardins, Cristina Suárez,

Investigational New Drugs

2020

125

Inhibition of Phosphodiesterase 4 Attenuates Airway Hyperresponsiveness and Airway Inflammation in a Model of Secondary Allergen Challenge

Arihiko Kanehiro, Toshihide Ikemura, Mika J. Mäkelä,

American Journal of Respiratory and Critical Care Medicine

2001

123

Page 1